Skip to main
CSTL

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. has demonstrated significant growth in its TissueCypher test, with test volume increasing by 92% year-over-year and 23% quarter-over-quarter in the second quarter of 2025, indicating strong market demand and effective sales force expansion. The company has also successfully improved the gross margin for the TissueCypher test, reporting an impressive 77% in the third quarter, which reflects operational efficiencies and profitability potential. With most of the gastrointestinal sales force expected to reach maturity in the second half of 2025, the outlook for continued revenue growth in this segment appears optimistic.

Bears say

Castle Biosciences Inc. faces a challenging outlook as its EV-to-estimated 2026/2027 revenue multiples for its dermatology and DecisionDx-UM tests are projected to be significantly lower than those for TissueCypher, indicating potential revenue pressures. A lack of clinician awareness, particularly within the gastroenterology sector, is identified as a major roadblock, suggesting that the company is struggling to penetrate the market effectively. Despite indications that the stock is undervalued from a conservative perspective, the fundamental concerns around market penetration and revenue generation raise doubts about its growth potential in the near term.

CSTL has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Strong Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.